Good deal compared to what?
I've seen where a BP paid
Good deal compared to what?
I've seen where a BP paid $700M for a preclinical drug that failed miserably and I'm sure there are others just like it.
How high is UP is another good question.
We are not dealing with a reformulated drug nor are we dealing with another "new" antibiotic in the cycline or mycin family.
If this was just "another drug" addressing an indication in an already competitive market,value assessment would be much easier.
However:
We are dealing with a whole new class of drug that addresses an unmet need in a totally and potentially vast untouched market .
We are dealing with a drug that so far has not shown any meaningful contraindications,side affects,or adverse reactions.What are "No Lawsuits" worth to a BP?
We are dealing with a drug that is easily administered,packaged,shipped and stored.What's that worth?
We are dealing with a drug that will be rapidly accepted by the medical community as well as the insurance industry.What's that worth?
We are dealing with a drug that will likely have global marketing from the start.What's that worth?
To quantify that in dollars and cents is not only above my "pay grade" but also likely far above yours as well.
Best not to talk about deal values and leave that up to those who know far more than any of us do.
Kelt
5
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...
Continue Reading
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...
Continue Reading
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Top 5 Most Recently Viewed Articles
ARK Venture Fund Invests in Umoja's Innovative Cancer Research Cathie Wood's ARK Venture Fund has made a notable investment in Umoja's Series C funding round, marking a significant milestone for the biotech company. Umoja is dedicated to pioneering a transformative approach to cancer treatment, focusing on enhancing the patient's immune response through novel techniques....
Continue Reading
Hooker Furnishings' Second Quarter Performance Hooker Furnishings Corporation (NASDAQ: HOFT), a well-established name in the home furnishings industry for more than a century, recently revealed its financial results for the second quarter of fiscal 2025. The company demonstrated resilience in the face of challenging market conditions. Sales Performance Insights Typically...
Continue Reading
Pulmonx Achieves Record Financial Success in 2024 Pulmonx Corporation (Nasdaq: LUNG) has made significant strides in its financial performance, demonstrating a remarkable growth trajectory throughout 2024. This globally recognized leader in minimally invasive lung disease treatments reported promising results that highlight its strong business model and commitment to...
Continue Reading
Blue Hat Interactive Entertainment Technology Engages in Direct Share Offering Recently, Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) made headlines by announcing its entry into securities purchase agreements allowing it to raise an impressive $4.3 million. This initiative is aimed at bolstering the company's financial stability and enhancing its market...
Continue Reading
PTx Trimble Triumphs with OutRun at the Davidson Prize OutRun Autonomous Grain Cart Now Available in the U.S. PTx Trimble, a collaboration between AGCO and Trimble that started in 2024, has made headlines by launching OutRun, a revolutionary autonomous grain cart that has just clinched the prestigious Davidson Prize at Commodity Classic 2025. This accolade recognizes...
Continue Reading